The main idea is that there is a federal law that bars paying or receiving kickbacks to influence referrals for items or services paid for by federal health care programs. This is the Anti-Kickback Statute. It makes it illegal to knowingly and willfully offer, pay, solicit, or receive any remuneration to induce or reward referrals for services or supplies that are reimbursed by programs like Medicare or Medicaid. The goal is to protect clinical judgment from financial incentives and protect program integrity. Penalties can be severe, including criminal fines, imprisonment, and exclusion from federal programs. There are safe harbors for certain arrangements that meet specific criteria, but outside those, such payments can lead to liability. The other statutes listed don’t govern referral incentives: the False Claims Act targets submitting false claims to the government; the Prescription Drug Marketing Act addresses drug marketing and distribution; and the Poison Prevention Packaging Act deals with packaging safety.

Under the FD&C Act, what makes a product a drug is its intended use to diagnose, cure, mitigate, treat, or prevent disease in humans or animals (and, more broadly, to affect the structure or function of the body). The statement describing articles intended for diagnosing, curing, mitigating, treating, or preventing disease matches that core criterion, so it best defines a drug. Foods are regulated separately as foods, not drugs. Devices are a distinct category with their own definitions, and pest-control products fall under EPA pesticide regulation, not FDA drug regulation.

GLP stands for Good Laboratory Practice, a regulatory quality system that ensures nonclinical laboratory studies used for regulatory submissions are planned, performed, monitored, recorded, reported, and archived in a standardized, controlled way. It sets requirements for study planning, qualifications of personnel, validated methods, proper facilities and equipment, appropriate handling of test and reference substances, detailed documentation, and reliable data reporting. This framework aims to guarantee the integrity and reliability of safety data submitted to authorities. General Laboratory Procedure is too vague and non-regulatory; it refers to routine steps rather than an overarching quality system. Good Laboratory Protocol would imply just a single protocol, whereas GLP governs the entire practice framework. Good Licensing Practice isn’t the recognized term in this regulatory context, and it doesn’t describe the systematic quality standards for nonclinical studies.

Generic drug equivalence means a generic product must be therapeutically equivalent to the brand-name drug, delivering the same active ingredient in the same dosage form and strength, by the same route, and meeting the same quality standards so its pharmacokinetic profile is the same enough to produce the same safety and efficacy. The statement that describes identical dosage form, strength, route of administration, and quality with identical performance characteristics best captures these requirements, because it implies both the same active ingredient (through the same dosage form and strength) and the same bioequivalence/therapeutic effect. This is why a generic should not differ in active ingredient, should not be tied to the same manufacturer as a requirement, and should not be used for a different indication.

The FDA’s authority to regulate the import of drugs comes from the Federal Food, Drug, and Cosmetic Act. This act grants the agency power to ensure that drugs entering the United States are safe, effective, properly labeled, and not adulterated or misbranded, and it provides authority to inspect, detain, and refuse admission of imported drugs that don’t meet those standards. The Public Health Service Act covers other public health areas but not the core authority for drug import regulation. Labeling rules are part of overall FD&C Act requirements, but the key source for regulating imports is the FD&C Act. Therefore, the Federal Food, Drug, and Cosmetic Act is the correct basis for regulating drug imports.